Diamyd Medical: Diamyd Updates FDA IND Approval Status For Phase III Diamyd(R) Diabet
Diamyd Medical (NASDAQ
MYDY) (STOIAMB) announced that it has received one FDA question relating to the US Phase III IND application for Diamyd? in treatment of type 1 diabetes. The question has been answered with additional documentation and the FDA now has 30 days to respond.
for more info, visit:
Diamyd Medical: Diamyd Updates FDA IND Approval Status For Phase III Diamyd(R) Diabetes Study In The US
MYDY) (STOIAMB) announced that it has received one FDA question relating to the US Phase III IND application for Diamyd? in treatment of type 1 diabetes. The question has been answered with additional documentation and the FDA now has 30 days to respond. for more info, visit:
Diamyd Medical: Diamyd Updates FDA IND Approval Status For Phase III Diamyd(R) Diabetes Study In The US
